Management of Elevated Fecal Calprotectin in Inflammatory Bowel Disease
Decision‑Making in Patients in Symptomatic Remission
- In patients with known IBD who are in symptomatic remission, a fecal calprotectin level > 150 mg/g (or CRP > 5 mg/L) should prompt endoscopic assessment rather than empiric escalation of therapy. 1, 3
- Re‑measuring calprotectin after 3–6 months is an acceptable alternative to immediate endoscopy; if the repeat test remains elevated, endoscopic evaluation becomes necessary. 1, 2, 3 → 2, 3, 4
- In Crohn’s disease, a calprotectin > 150 mg/g confers an approximately 4.8‑fold higher risk of clinical relapse within 12 months compared with normal levels. 1
- When remission has been achieved only 1–3 months ago after a treatment change, failure of calprotectin to normalize likely reflects ongoing inflammation and may justify treatment adjustment without waiting for endoscopy. 1, 2
Decision‑Making in Patients with Active Symptoms
- For moderate‑to‑severe symptoms suggestive of a flare, an elevated calprotectin > 150 mg/g can be used to confirm active inflammation and guide treatment adjustment, avoiding routine endoscopy solely for disease confirmation. 2, 3
- In the presence of mild symptoms together with calprotectin > 150 mg/g, endoscopic assessment is recommended rather than empiric treatment change. 3, 4
- Patients with severe symptoms who wish to minimize testing burden may elect to base treatment decisions on clinical presentation alone, acknowledging the biomarker’s supportive role. 2, 3
Diagnostic Thresholds and Test Performance
| Calprotectin Cut‑off | Sensitivity for Endoscopic Inflammation | Specificity for Endoscopic Inflammation | |
|---|---|---|---|
| < 50 mg/g | 88 % | 67 % | [2] |
| < 150 mg/g | 81 % | 72 % | [2] |
| < 250 mg/g | 76 % | 74 % | [1] |
- For ruling out active inflammation in patients in symptomatic remission, a threshold < 150 mg/g is recommended; a stricter threshold < 50 mg/g may be preferred when remission was achieved within the preceding 1–3 months. 2, 4
Pitfalls and Limitations
- Elevated calprotectin is not specific to IBD; infectious etiologies (e.g., Clostridioides difficile and other enteric pathogens) should be excluded first. 3
- In asymptomatic individuals with endoscopic remission, 20–26 % may still show elevated calprotectin, representing false‑positive results. 1
- False‑negative rates range from 2.4 % to 4.8 % depending on the cut‑off used, meaning a normal calprotectin does not completely rule out active disease. 1
- C‑reactive protein (CRP) has limited utility in ulcerative colitis for excluding moderate‑to‑severe endoscopic inflammation, especially shortly after treatment changes. 2, 4